CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative effect of accounting changes	Common Stock	Additional Paid-in Capital	Deferred Stock Units	Retained Earnings	Retained Earnings Cumulative effect of accounting changes	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Noncontrolling Interest
Balance beginning of period (in shares) at Dec. 31, 2019			105,711
Balance beginning of period at Dec. 31, 2019	$ 177,825	$ (1,829)	$ 10,571	$ 1,213,517	$ 4,462	$ 1,595,648	$ (1,829)	$ (46,182)	$ (2,600,543)	$ 352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	111,856					111,827				29
Other comprehensive income (loss), net	(9,064)							(9,064)
Repurchases of common stock	(187,767)								(187,767)
Common stock issued under stock plans, including excess tax benefit (in shares)			203
Common stock issued under stock plans, including excess tax benefit	9,750		$ 20	9,730
Share-based compensation cost	7,284			7,238	46
Balance end of period (in shares) at Mar. 31, 2020			105,914
Balance end of period at Mar. 31, 2020	108,055		$ 10,591	1,230,485	4,508	1,705,646		(55,246)	(2,788,310)	381
Balance beginning of period (in shares) at Dec. 31, 2019			105,711
Balance beginning of period at Dec. 31, 2019	177,825	$ (1,829)	$ 10,571	1,213,517	4,462	1,595,648	$ (1,829)	(46,182)	(2,600,543)	352
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	407,173
Other comprehensive income (loss), net	(15,743)
Balance end of period (in shares) at Sep. 30, 2020			106,282
Balance end of period at Sep. 30, 2020	441,115		$ 10,628	1,274,069	5,411	2,000,805		(61,925)	(2,788,412)	539
Balance beginning of period (in shares) at Mar. 31, 2020			105,914
Balance beginning of period at Mar. 31, 2020	108,055		$ 10,591	1,230,485	4,508	1,705,646		(55,246)	(2,788,310)	381
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	148,996					148,940				56
Other comprehensive income (loss), net	(1,786)							(1,786)
Issuance of common stock	258								258
Common stock issued under stock plans, including excess tax benefit (in shares)			117
Common stock issued under stock plans, including excess tax benefit	10,080		$ 12	10,068	0
Deferred stock units activity	0			(894)	894
Share-based compensation cost	7,797			7,797	0
Balance end of period (in shares) at Jun. 30, 2020			106,031
Balance end of period at Jun. 30, 2020	273,400		$ 10,603	1,247,456	5,402	1,854,586		(57,032)	(2,788,052)	437
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	146,321					146,219				102
Other comprehensive income (loss), net	(4,893)							(4,893)
Repurchases of common stock	(360)								(360)
Common stock issued under stock plans, including excess tax benefit (in shares)			251
Common stock issued under stock plans, including excess tax benefit	18,719		$ 25	18,706	(12)
Share-based compensation cost	7,928			7,907	21
Balance end of period (in shares) at Sep. 30, 2020			106,282
Balance end of period at Sep. 30, 2020	$ 441,115		$ 10,628	1,274,069	5,411	2,000,805		(61,925)	(2,788,412)	539
Balance beginning of period (in shares) at Dec. 31, 2020	106,457		106,457
Balance beginning of period at Dec. 31, 2020	$ 632,795		$ 10,646	1,294,849	4,503	2,175,595		(53,615)	(2,799,890)	707
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	204,289					204,257				32
Other comprehensive income (loss), net	(5,921)							(5,921)
Repurchases of common stock	(154,033)								(154,033)
Common stock issued under stock plans, including excess tax benefit (in shares)			219
Common stock issued under stock plans, including excess tax benefit	17,430		$ 22	17,408
Share-based compensation cost	8,875			8,829	46
Balance end of period (in shares) at Mar. 31, 2021			106,676
Balance end of period at Mar. 31, 2021	$ 703,435		$ 10,668	1,321,086	4,549	2,379,852		(59,536)	(2,953,923)	739
Balance beginning of period (in shares) at Dec. 31, 2020	106,457		106,457
Balance beginning of period at Dec. 31, 2020	$ 632,795		$ 10,646	1,294,849	4,503	2,175,595		(53,615)	(2,799,890)	707
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	582,073
Other comprehensive income (loss), net	$ 1,558
Balance end of period (in shares) at Sep. 30, 2021	106,806		106,806
Balance end of period at Sep. 30, 2021	$ 755,460		$ 10,681	1,358,813	5,669	2,757,669		(52,057)	(3,326,021)	706
Balance beginning of period (in shares) at Mar. 31, 2021			106,676
Balance beginning of period at Mar. 31, 2021	703,435		$ 10,668	1,321,086	4,549	2,379,852		(59,536)	(2,953,923)	739
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	202,606					202,582				24
Other comprehensive income (loss), net	11,145							11,145
Repurchases of common stock	(188,378)								(188,378)
Common stock issued under stock plans, including excess tax benefit (in shares)			72
Common stock issued under stock plans, including excess tax benefit	9,778		$ 7	9,771
Deferred stock units activity	0			(1,035)	1,035
Share-based compensation cost	9,637			9,591	46
Balance end of period (in shares) at Jun. 30, 2021			106,748
Balance end of period at Jun. 30, 2021	748,223		$ 10,675	1,339,413	5,630	2,582,434		(48,391)	(3,142,301)	763
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	175,178					175,235				(57)
Other comprehensive income (loss), net	(3,666)							(3,666)
Repurchases of common stock	(183,720)								(183,720)
Common stock issued under stock plans, including excess tax benefit (in shares)			58
Common stock issued under stock plans, including excess tax benefit	9,915		$ 6	9,921	(12)
Share-based compensation cost	$ 9,530			9,479	51
Balance end of period (in shares) at Sep. 30, 2021	106,806		106,806
Balance end of period at Sep. 30, 2021	$ 755,460		$ 10,681	$ 1,358,813	$ 5,669	$ 2,757,669		$ (52,057)	$ (3,326,021)	$ 706